Arcadia Capital Advisors Recommends Accelrys Inc. Return Cash to Shareholders
September 27, 2010 08:05 ET
|
Arcadia Capital Advisors, LLC
NEW YORK, Sept. 27, 2010 (GLOBE NEWSWIRE) -- Arcadia Capital Advisors, LLC ("Arcadia"), a shareholder of Accelrys, Inc., ("Accelrys", or the "Company") (Nasdaq:ACCL), and its managing director,...
Arcadia Capital Advisors Urges Cypress Bioscience to Explore Alternatives, Not Acquisitions
September 07, 2010 08:00 ET
|
Arcadia Capital Advisors, LLC
NEW YORK, Sept. 7, 2010 (GLOBE NEWSWIRE) -- Arcadia Capital Advisors, LLC ("Arcadia"), a shareholder of Cypress Bioscience Inc. ("Cypress" or the "Company"), and its managing director, Richard S....
Arcadia Capital Advisors Urges Symyx Board of Directors to Consider Competing Cash Bids
May 26, 2010 08:00 ET
|
Arcadia Capital Advisors, LLC
NEW YORK, May 26, 2010 (GLOBE NEWSWIRE) -- Arcadia Capital Advisors, LLC ("Arcadia") and its managing director, Richard S. Rofe ("Rofe"), a shareholder of Symyx Technologies ("Symyx"), reported that...
Arcadia Capital Advisors Managing Director Richard S. Rofe Announces Expiration of Tender Offer for CPEX Pharmaceuticals
May 24, 2010 17:47 ET
|
Arcadia Capital Advisors, LLC
NEW YORK, May 24, 2010 (GLOBE NEWSWIRE) -- Richard Rofe today announced the expiration of the previously-announced tender offer (the "Offer") for all outstanding common shares of CPEX Pharmaceuticals,...
Arcadia Capital Advisors Managing Director Richard S. Rofe Comments on CPEX Pharmaceuticals Board Recommended Rejection of Tender Offer
May 06, 2010 19:15 ET
|
Arcadia Capital Advisors, LLC
NEW YORK, May 6, 2010 (GLOBE NEWSWIRE) -- Arcadia Capital Advisors, LLC, Managing Director Richard S. Rofe, issued a statement in response to a press release issued this morning by CPEX...
Arcadia Capital Advisors Managing Director Richard S. Rofe Comments on CPEX Pharmaceuticals Board Recommended Rejection of Tender Offer
May 06, 2010 18:09 ET
|
Arcadia Capital Advisors, LLC
NEW YORK, May 6, 2010 (GLOBE NEWSWIRE) -- Arcadia Capital Advisors, LLC, Managing Director Richard S. Rofe, issued a statement in response to a press release issued this morning by CPEX...
Richard S. Rofe Announces Commencement of All-Cash $16.00 Per Share Tender Offer for CPEX Pharmaceuticals Through RSR Acquisition Co., a Wholly-Owned Subsidiary of Shelter Bay Holdings, LLC
April 23, 2010 07:00 ET
|
Arcadia Capital Advisors, LLC
NEW YORK, April 23, 2010 (GLOBE NEWSWIRE) -- Arcadia Capital Advisors Managing Director Richard Rofé announced today that he has commenced a $16.00 per share all-cash tender offer for CPEX...
Arcadia Capital Advisors Managing Director Richard S. Rofe Responds to CPEX Management's Most Recent Statements
April 13, 2010 11:48 ET
|
Arcadia Capital Advisors, LLC
Agrees With Long Overdue Decision to Terminate Nasulin Program on Which Arcadia Believes CPEX Management Misapplied $17 Million in Failed R&D in First Eighteen Months as Public Company
CPEX...
Arcadia Capital Advisors Managing Director Richard S. Rofe Comments on CPEX Pharmaceuticals' Recent Partner News
April 05, 2010 18:14 ET
|
Arcadia Capital Advisors, LLC
News Reinforces Premise That Current CPEX Strategy Misguided
Rofé Questions Management Strategy to Continue Pursuit of Internal Drug Development
NEW YORK, April 5, 2010 (GLOBE NEWSWIRE) --...
Arcadia Capital Advisors Managing Director Richard S. Rofe Comments on CPEX Pharmaceuticals' Failed Nasulin Phase 2a Trial
March 19, 2010 08:55 ET
|
Arcadia Capital Advisors, LLC
Reiterates Need for CPEX Board to Exercise Independence and Fiduciary Duty
Raises Issue of Possible Fraud Being Perpetrated on CPEX Shareholders
NEW YORK, March 19, 2010 (GLOBE NEWSWIRE) --...